T. Rowe Price Associates’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$231K Buy
29,793
+3,679
+14% +$26.8K ﹤0.01% 2789
2025
Q4
$161K Sell
26,114
-1,838
-7% -$19.9K ﹤0.01% 2858
2025
Q3
$516K Buy
27,952
+4,679
+20% +$75.2K ﹤0.01% 2341
2025
Q2
$303K Buy
23,273
+3,152
+16% +$37.3K ﹤0.01% 2521
2025
Q1
$214K Buy
20,121
+1,103
+6% +$17.5K ﹤0.01% 2599
2024
Q4
$323K Buy
19,018
+1,279
+7% +$24.1K ﹤0.01% 2478
2024
Q3
$412K Buy
17,739
+122
+0.7% +$2.61K ﹤0.01% 2335
2024
Q2
$429K Buy
17,617
+613
+4% +$18.6K ﹤0.01% 2249
2024
Q1
$575K Buy
17,004
+922
+6% +$32.7K ﹤0.01% 2154
2023
Q4
$508K Buy
16,082
+360
+2% +$8.56K ﹤0.01% 2162
2023
Q3
$402K Sell
15,722
-3,535
-18% -$109K ﹤0.01% 2215
2023
Q2
$553K Sell
19,257
-617
-3% -$16.8K ﹤0.01% 2078
2023
Q1
$477K Buy
19,874
+105
+0.5% +$1.88K ﹤0.01% 2127
2022
Q4
$335K Buy
19,769
+1,522
+8% +$26.5K ﹤0.01% 2328
2022
Q3
$271K Buy
18,247
+1,515
+9% +$25.4K ﹤0.01% 2422
2022
Q2
$263K Buy
16,732
+410
+3% +$8.05K ﹤0.01% 2496
2022
Q1
$440K Buy
16,322
+1,283
+9% +$32.7K ﹤0.01% 2393
2021
Q4
$557K Buy
15,039
+298
+2% +$12.1K ﹤0.01% 2335
2021
Q3
$704K Sell
14,741
-119,000
-89% -$5.33M ﹤0.01% 2213
2021
Q2
$4.53M Sell
133,741
-49,328
-27% -$1.67M ﹤0.01% 1522
2021
Q1
$7.56M Sell
183,069
-1,239,110
-87% -$73.9M ﹤0.01% 1426
2020
Q4
$61.7M Buy
1,422,179
+718,793
+102% +$48.7M 0.01% 882
2020
Q3
$30.2M Buy
703,386
+185,549
+36% +$9.21M ﹤0.01% 1037
2020
Q2
$24.2M Buy
+517,837
New +$17.8M ﹤0.01% 1095

Other funds holding ARCT